<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Fluconazole - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Fluconazole</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Fluconazole</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Fluconazole 150mg Tablets</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Vulvovaginal candidiasis (uncomplicated)</strong>
            <ul>
              <li>150 mg PO once (single dose)</li>
            </ul>
          </li>
          <li><strong>Severe vulvovaginal candidiasis</strong> (if significant symptoms; follow local guidance)
            <ul>
              <li>150 mg PO, then repeat 150 mg PO 72 hours later (some cases may require an additional dose per guidance/clinical judgment)</li>
            </ul>
          </li>
          <li><strong>Candidal balanitis</strong> (selected cases; if clinician-directed)
            <ul>
              <li>150 mg PO once</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Vulvovaginal candidiasis (single-dose oral treatment)</li>
          <li>Selected mucocutaneous Candida infections where oral fluconazole is appropriate (clinician-directed)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Contraindicated in known fluconazole/azole hypersensitivity</li>
          <li>Pregnancy: avoid oral fluconazole for vaginal candidiasis in pregnancy when possible; prefer topical therapy (risk-benefit)</li>
          <li>Hepatic risk: caution in significant liver disease; hepatotoxicity is rare but possible</li>
          <li>QT prolongation risk: caution with known long QT, electrolyte abnormalities, or other QT-prolonging drugs</li>
          <li>Major drug interaction potential (CYP inhibition):
            <ul>
              <li>Warfarin (↑ INR/bleeding risk)</li>
              <li>Some sulfonylureas (hypoglycemia risk)</li>
              <li>Some statins (myopathy risk) and other CYP-metabolized agents</li>
              <li>Review med list when feasible, especially if repeat dosing planned</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Headache, nausea, abdominal discomfort/diarrhea</li>
          <li>Rash (rare severe reactions)</li>
          <li>Rare/serious: hepatotoxicity, QT prolongation/arrhythmia</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>Single 150 mg PO dose: with or without food</li>
          <li>Counsel: symptom improvement may take 24–72 hours; persistent symptoms need reassessment (diagnosis/complicated infection)</li>
          <li>If repeat dosing is used: document each dose date/time clearly and reassess symptoms</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>For single-dose use: usually symptom-based monitoring only</li>
          <li>If repeat/prolonged therapy: consider LFTs and interaction monitoring per clinician judgment</li>
          <li>If on warfarin: consider INR monitoring if feasible</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Screen for pregnancy when relevant; topical alternatives may be preferred in pregnancy</li>
          <li>Keep a simple "single-dose given" note with date/time to avoid duplicate dosing</li>
          <li>If symptoms persist or recur, consider limited diagnostics at sea and plan follow-up/evac guidance based on severity and risk factors</li>
          <li>Interaction risk: if the patient is on multiple meds, do a quick interaction check before repeat dosing if feasible</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li><a href="https://pdf.hres.ca/dpd_pm/00076033.PDF" target="_blank" rel="noopener">Health Canada product monograph (Fluconazole-150)</a></li>
          <li><a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/non-prescription-fluconazole-assessing-potential-risks-pregnancy-outcomes.html" target="_blank" rel="noopener">Health Canada safety review (fluconazole 150 mg and pregnancy outcomes)</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
